MTCO2P17

Across TCGA pan-cancer cohorts, MTCO2P17 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MTCO2P17’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where MTCO2P17 RNA is repressed in tumor relative to normal tissue. In most cancer types MTCO2P17 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA and KIRC are the cancer types where MTCO2P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCO2P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.032	.032	4	view →
KIRC	Male	IV	−0.022	.037	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

MTCO2P17–THCA

Open the THCA breakdown →